An inverse agonist at CB2 and partial agonist at CB1 receptors
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

AM630

Item No. 10006974

Product Insert (PDF)GC-MS (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
[6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone
CAS Number
164178-33-0
Synonyms
  • 6-Iodopravodoline
Molecular Formula
C23H25IN2O3
Formula Weight
504.4
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMF:PBS (pH 7.2) 1:4: 0.2 mg/mlDMSO: 3 mg/ml
λmax
229, 283 nm
SMILES
COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12
InChi Code
InChI=1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3
InChi Key
JHOTYHDSLIUKCJ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $63

    Add

    10 mg

    $118

    Add

    50 mg

    $454

    Add

    100 mg

    $842

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.1 AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.1,2,3 It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ross, R.A., Brockie, H.C., Stevenson, L.A., et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol. 126(3), 665-672 (1999).

    2. Malan, T.P., Jr., Ibrahim, M.M., Deng, H., et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93(3), 239-245 (2001).

    3. Bisogno, T., Ortar, G., Petrosino, S., et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim. Biophys. Acta 1791(1), 53-60 (2009).

    4. Wang, J., Xu, Y., Zhu, L., et al. Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression. J. Cancer Res. Clin. Oncol. (2017).

    Product Citations

    Roberto, D., Klotz, L.H., and Venkateswaran, V. Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner. Prostate (2018).

    McDougle, D.R., Watson, J.E., Abdeen, A.A., et al. Anti-inflammatory ω-3 endocannabinoid epoxides. Proc. Natl. Acad. Sci. USA 114(30), E6034-E6043 (2017).

    Ribeiro, R., Wen, J., Li, S., et al. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat. 100-101, (2013).

    Bishay, P., Schmidt, H., Marian, C., et al. R-Flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One 5(5), e10628 (2010).